<DOC>
	<DOCNO>NCT00150709</DOCNO>
	<brief_summary>The open-label study allow pediatric patient participate prior Levetiracetam ( Keppra® ) study continue treatment adequate monitoring standardize follow-up care Levetiracetam ( Keppra® ) approve use child completion development program pediatrics .</brief_summary>
	<brief_title>A Study Of The Safety And Efficacy Of Levetiracetam ( Keppra® ) ( Ucb L059 ) In Children With Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Have complete Study N151 , applicable pediatric trial Levetiracetam ( Keppra® ) Be patient treatment Levetiracetam ( Keppra® ) would potential benefit patient/parent ( ) /legal guardian Investigator agree continue treatment . Not ketogenic diet ( course study ) . Not seizures close together accurately count ( i.e. , patient 's seizure must countable ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Epilepsy , Pediatric , partial onset epilepsy ,</keyword>
	<keyword>Levetiracetam ( Keppra® )</keyword>
</DOC>